蒋怡然, 王卫庆 . 原发性醛固酮增多症的诊治现状及展望[J]. 诊断学理论与实践, 2020 , 19(05) : 445 -449 . DOI: 10.16150/j.1671-2870.2020.05.001
| [1] | Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice[J]. J Am Coll Cardiol, 2017, 69(14):1811-1820. |
| [2] | 中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9):727-736. |
| [3] | Sang X, Jiang Y, Wang W, et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China[J]. J Hypertens, 2013, 31(7):1465-1471. |
| [4] | Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension[J]. J Am Coll Cardiol, 2020, 75(16):1913-1922. |
| [5] | Hu Y, Zhang J, Liu W, et al. Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension[J]. J Clin Endocrinol Metab, 2020, 105(4):dgz293. |
| [6] | Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients[J]. Arch Intern Med, 1981, 141(12):1589-1593. |
| [7] | Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2016, 101(5):1889-1916. |
| [8] | Burrello J, Monticone S, Buffolo F, et al. Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism[J]. J Hypertens, 2016, 34(5):920-977. |
| [9] | Glinicki P, Jeske W, Bednarek-Papierska L, et al. The ratios of aldosterone / plasma renin activity (ARR) versus aldosterone / direct renin concentration(ADRR)[J]. J Renin Angiotensin Aldosterone Syst, 2015, 16(4):1298-1305. |
| [10] | Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives[J]. J Intern Med, 2019, 285(2):126-148. |
| [11] | 宋颖, 何文雯, 杨淑敏, 等. 化学发光法测定血浆醛固酮浓度/肾素浓度比值筛查原发性醛固酮增多症的[J]. 中华内科杂志, 2016, 55(1):6-10. |
| [12] | Li Y, Liu Y, Li J, et al. Sodium infusion test for diagnosis of primary aldosteronism in chinese population[J]. J Clin Endocrinol Metab, 2016, 101(1):89-95. |
| [13] | Wang K, Hu J, Yang J, et al. Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism[J]. J Clin Endocrinol Metab, 2020, 105(7):dgaa282. |
| [14] | Song Y, Yang S, He W, et al. Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study[J]. Hypertension, 2018, 71(1):118-124. |
| [15] | 陈适, 曾正陪, 宋爱羚, 等. 卡托普利试验在原发性醛固酮增多症诊断中的应用[J]. 中华内科杂志, 2017, 56(6):402-408. |
| [16] | Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism[J]. Hypertension, 2014, 63(1):151-160. |
| [17] | Ma D, Liu X, Zeng L, et al. The role of adrenal venous sampling and computed tomography in the management of primary aldosteronism[J]. J Hypertens. 2020-08-29 [2020/ 10/ 16]. https://pubmed.ncbi.nlm.nih.gov/32868641/. |
| [18] | Jiang Y, Zhang C, Wang W, et al. Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism[J]. J Clin Endocrinol Metab, 2015, 100(5):1837-1844. |
| [19] | Küpers EM, Amar L, Raynaud A, et al. A clinical prediction score to diagnose unilateral primary aldosteronism[J]. J Clin Endocrinol Metab, 2012, 97(10):3530-3537. |
| [20] | Zhang Y, Niu W, Zheng F, et al. Identifying unilateral disease in Chinese patients with primary aldosteronism by using a modified prediction score[J]. J Hypertens, 2017, 35(12):2486-2492. |
| [21] | Xiao L, Jiang Y, Zhang C, et al. A novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism[J]. Clin Endocrinol (Oxf), 2019, 90(6):781-788. |
| [22] | 蒋怡然, 张翠, 姜蕾, 等. 螺内酯单药治疗及低剂量螺内酯联合治疗特发性醛固酮增多症的有效性及安全性[J]. 中华内分泌代谢杂志, 2018, 34(6):479-484. |
| [23] | Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism[J]. Expert Opin Pharmacother, 2008, 9(4):509-515. |
| [24] | Amar L, Azizi M, Menard J, et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism[J]. Hypertension, 2010, 56(5):831-838. |
| [25] | Bogman K, Schwab D, Delporte ML, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase(CYP11B2)[J]. Hypertension, 2017, 69(1):189-196. |
| [26] | Zheng FF, Zhu LM, Nie AF, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma[J]. Hypertension, 2015, 65(3):622-628. |
| [27] | Li X, Wang B, Tang L, et al. GSTA1 expression is correlated with aldosterone level in KCNJ5-mutated adrenal aldosterone-producing adenoma[J]. J Clin Endocrinol Metab, 2018, 103(3):813-823. |
| [28] | Cao Y, Zhou W, Li L, et al. Pan-cancer analysis of somatic mutations across 21 neuroendocrine tumor types[J]. Cell Res, 2018, 28(5):601-604. |
| [29] | Omata K, Satoh F, Morimoto R, et al. Cellular and gene-tic causes of idiopathic hyperaldosteronism[J]. Hypertension, 2018, 72(4):874-880. |
/
| 〈 |
|
〉 |
